These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

921 related articles for article (PubMed ID: 9476320)

  • 21. Efficiency of ultrasound and biochemical markers for Down's syndrome risk screening. A prospective study.
    Benattar C; Audibert F; Taieb J; Ville Y; Roberto A; Lindenbaum A; Frydman R
    Fetal Diagn Ther; 1999; 14(2):112-7. PubMed ID: 10085510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-trimester Down's syndrome screening using nuchal translucency: a prospective study in patients undergoing chorionic villus sampling.
    Brambati B; Cislaghi C; Tului L; Alberti E; Amidani M; Colombo U; Zuliani G
    Ultrasound Obstet Gynecol; 1995 Jan; 5(1):9-14. PubMed ID: 7850598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities.
    Zimmermann R; Hucha A; Savoldelli G; Binkert F; Achermann J; Grudzinskas JG
    Br J Obstet Gynaecol; 1996 Oct; 103(10):1009-14. PubMed ID: 8863700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study.
    Crossley JA; Aitken DA; Cameron AD; McBride E; Connor JM
    BJOG; 2002 Jun; 109(6):667-76. PubMed ID: 12118646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prenatal Down's syndrome screening at 10-14 weeks gestation using the combined nuchal translucency and maternal serum biochemistry: preliminary results of the first 358 cases].
    Maymon R; Bergman M; Segal S; Dreazen E; Weinraub Z; Herman A
    Harefuah; 2001 Jul; 140(7):594-9, 679. PubMed ID: 11481959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome.
    Kadir RA; Economides DL
    Ultrasound Obstet Gynecol; 1997 Apr; 9(4):244-7. PubMed ID: 9168574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland.
    Niemimaa M; Suonpää M; Perheentupa A; Seppälä M; Heinonen S; Laitinen P; Ruokonen A; Ryynänen M
    Eur J Hum Genet; 2001 Jun; 9(6):404-8. PubMed ID: 11436120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of a programme for the prenatal screening for Down's syndrome by ultrasonographic nuchal translucency measurement and serum determinations in the first trimester of pregnancy].
    Go AT; Hupkes HW; Lomecky M; Twisk J; Blankenstein JM; van Vugt JM
    Ned Tijdschr Geneeskd; 2005 Dec; 149(50):2795-9. PubMed ID: 16385832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free β-hCG and PAPP-A: a 5-year prospective study.
    Ghaffari SR; Tahmasebpour AR; Jamal A; Hantoushzadeh S; Eslamian L; Marsoosi V; Fattahi F; Rajaei M; Niroomanesh S; Borna S; Beigi A; Khazardoost S; Saleh-Gargari S; Rahimi-Sharbaf F; Farrokhi B; Bayani N; Tehrani SE; Shahsavan K; Farzan S; Moossavi S; Ramezanzadeh F; Dastan J; Rafati M
    Ultrasound Obstet Gynecol; 2012 May; 39(5):528-34. PubMed ID: 21793085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-trimester urine free beta hCG, beta core, and total oestriol in pregnancies affected by Down's syndrome: implications for first-trimester screening with nuchal translucency and serum free beta hCG.
    Spencer K; Noble P; Snijders RJ; Nicolaides KH
    Prenat Diagn; 1997 Jun; 17(6):525-38. PubMed ID: 9203211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.
    Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012599. PubMed ID: 28295159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First trimester nuchal translucency: effective routine screening for Down's syndrome.
    Thilaganathan B; Sairam S; Michailidis G; Wathen NC
    Br J Radiol; 1999 Oct; 72(862):946-8. PubMed ID: 10673944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First trimester Down's syndrome screening shows high detection rate for trisomy 21, but poor performance in structural abnormalities--regional outcome results.
    Rissanen A; Niemimaa M; Suonpää M; Ryynänen M; Heinonen S
    Fetal Diagn Ther; 2007; 22(1):45-50. PubMed ID: 17003556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies.
    Audibert F; Gagnon A; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):754-67. PubMed ID: 21749753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening of maternal serum for fetal Down's syndrome in the first trimester.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Miller WA; Johnson A
    N Engl J Med; 1998 Apr; 338(14):955-61. PubMed ID: 9521983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-trimester nuchal translucency and maternal serum biochemical screening for Down's syndrome: a happy union?
    Thilaganathan B
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):229-30. PubMed ID: 10341398
    [No Abstract]   [Full Text] [Related]  

  • 39. Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness.
    Noble PL; Abraha HD; Snijders RJ; Sherwood R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1995 Dec; 6(6):390-5. PubMed ID: 8903913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population.
    Scott F; Peters H; Bonifacio M; McLennan A; Boogert A; Kesby G; Anderson J
    Aust N Z J Obstet Gynaecol; 2004 Jun; 44(3):205-9. PubMed ID: 15191443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.